Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

This study (n=150; 148 mild to moderate disease) found no statistically significant difference in the probability of negative conversion by 28 days between the standard of care plus hydroxychloroquine group and the standard of care group (difference 4.1%; 95% CI–10.3% to 18.5%).


British Medical Journal